This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Receptor for advanced glycation end products (RAGE), along with its ligand high mobility group box 1 (HMGB1),
is believed to play an important role in prostate cancer. The aim of this retrospective study was to investigate the co-expression of
RAGE and HMGB1, as well as their clinical meanings in prostate cancer.
Eighty-five patients with prostate cancer who underwent surgery or biopsy were enrolled in this study. The expression
of RAGE and HMGB1 were assessed by immunohistochemistry. Then we analyzed the association of expression level of RAGE
and HMGB1 with the clinicopathological features and overall survival in patients with prostate cancer.
The positive expression of RAGE and HMGB1 was in 78.8% (67/85) and 68.2% (58/85), while the co-expression of them
was occurred in 63.5% (54/85) of prostate cancer. The correlation of RAGE and HMGB1 expression was positive correlation
(P<0.05). The expression of RAGE, HMGB1 and their co-expression was correlated with tumor late stage (P<0.05). RAGE
expression also associated with the prostate special antigen (PSA) value. However, RAGE, HMGB1 and their co-expression was
not significantly related with age and Gleason score. The co-expression of RAGE and HMGB1 had poorer overall survival in
patients with stage III and IV of prostate cancer.
These results suggest that the expression of RAGE and HMGB1 was correlated with the progression and poor
prognosis of prostate cancer. RAGE and HMGB1 could be new biomarkers and played an important role in diagnosis, treatment
and prognosis of prostate cancer.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals